Celcuity (NASDAQ:CELC - Free Report) had its price objective upped by Needham & Company LLC from $23.00 to $29.00 in a research report report published on Thursday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.
Separately, HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $30.17.
Read Our Latest Stock Analysis on CELC
Celcuity Stock Performance
NASDAQ CELC traded down $0.36 on Thursday, hitting $11.89. 64,899 shares of the stock were exchanged, compared to its average volume of 238,736. The company has a market capitalization of $441.62 million, a PE ratio of -4.56 and a beta of 0.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. The business's fifty day moving average is $12.30 and its 200 day moving average is $14.35. Celcuity has a 52 week low of $10.35 and a 52 week high of $22.19.
Institutional Trading of Celcuity
Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in Celcuity by 2,083.4% during the third quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company's stock worth $673,000 after acquiring an additional 43,044 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Celcuity by 27.6% during the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company's stock worth $9,401,000 after purchasing an additional 136,518 shares during the last quarter. State Street Corp lifted its holdings in Celcuity by 152.2% during the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company's stock worth $16,512,000 after purchasing an additional 668,318 shares during the last quarter. Braidwell LP boosted its stake in Celcuity by 71.2% in the 3rd quarter. Braidwell LP now owns 884,306 shares of the company's stock valued at $13,185,000 after purchasing an additional 367,663 shares during the period. Finally, Barclays PLC grew its holdings in Celcuity by 567.6% in the 3rd quarter. Barclays PLC now owns 53,605 shares of the company's stock valued at $800,000 after buying an additional 45,576 shares in the last quarter. Institutional investors own 63.33% of the company's stock.
About Celcuity
(
Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
